The deal size was increased to $450M in common stock from $300M in common stock. Leerink, Piper Sandler, Guggenheim and Wells Fargo acted as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant Announces Pricing of $450 Million Common Stock Financing
- Immunovant price target raised to $48 from $32 at Guggenheim
- Immunovant price target raised to $48 from $33 at Wells Fargo
- Immunovant price target raised to $49 from $29 at BofA
- Immunovant price target raised to $50 from $33 at Citi